| BET inhibitor resistance emerges from leukaemia stem cells CY Fong, O Gilan, EYN Lam, AF Rubin, S Ftouni, D Tyler, K Stanley, ... Nature 525 (7570), 538-542, 2015 | 517 | 2015 |
| Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia MA Dawson, EJ Gudgin, SJ Horton, G Giotopoulos, E Meduri, S Robson, ... Leukemia 28 (2), 311-320, 2014 | 175 | 2014 |
| Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia CC Bell, KA Fennell, YC Chan, F Rambow, MM Yeung, D Vassiliadis, ... Nature communications 10 (1), 2723, 2019 | 148 | 2019 |
| Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy CC Chua, AW Roberts, J Reynolds, CY Fong, SB Ting, JM Salmon, ... Journal of Clinical Oncology 38 (30), 3506-3517, 2020 | 137 | 2020 |
| Functional interdependence of BRD4 and DOT1L in MLL leukemia O Gilan, EYN Lam, I Becher, D Lugo, E Cannizzaro, G Joberty, A Ward, ... Nature structural & molecular biology 23 (7), 673-681, 2016 | 104 | 2016 |
| Epigenetics in the hematologic malignancies CY Fong, J Morison, MA Dawson Haematologica 99 (12), 1772, 2014 | 95 | 2014 |
| Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population N Hein, DP Cameron, KM Hannan, NYN Nguyen, CY Fong, J Sornkom, ... Blood, The Journal of the American Society of Hematology 129 (21), 2882-2895, 2017 | 85 | 2017 |
| Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia IS Tiong, R Dillon, A Ivey, TC Teh, P Nguyen, N Cummings, DC Taussig, ... British journal of haematology 192 (6), 1026-1030, 2021 | 73 | 2021 |
| Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes P Yeh, M Dickinson, S Ftouni, T Hunter, D Sinha, SQ Wong, R Agarwal, ... Blood, The Journal of the American Society of Hematology 129 (12), 1685-1690, 2017 | 65 | 2017 |
| Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase … JS Garcia, AH Wei, U Borate, CY Fong, MR Baer, F Nolte, JG Jurcic, ... Blood 136, 55-57, 2020 | 61 | 2020 |
| A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-naïve patients with higher-risk myelodysplastic syndrome AH Wei, JS Garcia, U Borate, CY Fong, MR Baer, F Nolte, P Peterlin, ... Blood 134, 568, 2019 | 48 | 2019 |
| Molecular responses are observed across mutational spectrum in treatment-naïve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine JS Garcia, AH Wei, MA Jacoby, CY Fong, U Borate, MR Baer, ... Blood 138, 241, 2021 | 25 | 2021 |
| Molecular patterns of response and outcome in the chemotherapy and venetoclax in elderly AML trial (CAVEAT study) AH Wei, CC Chua, S Tiong, CY Fong, SB Ting, S Macraild, JM Salmon, ... Blood 132, 333, 2018 | 19 | 2018 |
| Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse CY Fong, G Grigoriadis, J Hocking, J Coutsouvelis, J Muirhead, ... Leukemia & Lymphoma 54 (2), 336-341, 2013 | 18 | 2013 |
| Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse ABM Lim, C Curley, CY Fong, I Bilmon, A Beligaswatte, D Purtill, B Getta, ... Internal Medicine Journal 48 (3), 276-285, 2018 | 16 | 2018 |
| Safety and efficacy of induction and maintenance avelumab plus R-CHOP in patients with diffuse large B-cell lymphoma (DLBCL): analysis of the Phase II Avr-CHOP Study EA Hawkes, G Chong, C Smith, ST Lee, L Churilov, J McKendrick, ... Blood 136, 43-44, 2020 | 14 | 2020 |
| Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy J Othman, IS Tiong, J O'Nions, M Dennis, K Mokretar, A Ivey, M Austin, ... Blood 143 (4), 336-341, 2024 | 13 | 2024 |
| A phase 1 study of Flotetuzumab, a CD123 x CD3 DART® protein, combined with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory acute myeloid leukemia AH Wei, CY Fong, P Montesinos, M Calbacho, JS Gil, JP De Oteyza, ... Blood 134, 2662, 2019 | 12 | 2019 |
| Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system C Parker, D Ayton, E Zomer, D Liew, C Vassili, CY Fong, A Wei Leukemia research 113, 106786, 2022 | 11 | 2022 |
| A prospective phase 2 study of venetoclax and low dose ara-C (VALDAC) to target rising molecular measurable residual disease and early relapse in acute myeloid leukemia IS Tiong, D Hiwase, EU Abro, A Bajel, E Palfreyman, S Loo, S Fleming, ... Blood 140 (Supplement 1), 1453-1455, 2022 | 9 | 2022 |
